BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34734237)

  • 1. Importance of tumour volume and histology in trimodality treatment of patients with Stage IIIA non-small cell lung cancer-results from a retrospective analysis.
    Joosten PJM; Dickhoff C; van der Noort V; Smeekens M; Numan RC; Klomp HM; van Diessen JNA; Belderbos JSA; Smit EF; Monkhorst K; Oosterhuis JWA; van den Heuvel MM; Dahele M; Hartemink KJ
    Interact Cardiovasc Thorac Surg; 2022 Mar; 34(4):566-575. PubMed ID: 34734237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function.
    Dickhoff C; Hartemink KJ; van de Ven PM; van Reij EJ; Senan S; Paul MA; Smit EF; Dahele M
    Lung Cancer; 2014 Aug; 85(2):218-23. PubMed ID: 24976333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
    Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of surgery for stage IIIa non-small cell lung cancer].
    Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
    Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy.
    Moore S; Leung B; Wu J; Ho C
    J Thorac Oncol; 2019 Aug; 14(8):1430-1439. PubMed ID: 31002953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.
    Senan S; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Murakami S; Hui R; Faivre-Finn C; Paz-Ares L; Wu YL; Mann H; Dennis PA; Antonia SJ
    ESMO Open; 2022 Apr; 7(2):100410. PubMed ID: 35247871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.
    Finkle JH; Jo SY; Ferguson MK; Liu HY; Zhang C; Zhu X; Yuan C; Pu Y
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1275-1284. PubMed ID: 28265739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.
    Thibodeau S; Meem M; Hopman W; Sandhu S; Zalay O; Fung AS; Kartolo A; Digby GC; Al-Ghamdi S; Robinson A; Ashworth A; Owen T; Mahmud A; Tam K; Olding T; de Moraes FY
    Cancer Treat Res Commun; 2023; 36():100747. PubMed ID: 37531737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
    Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
    Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013.
    Dickhoff C; Dahele M; de Langen AJ; Paul MA; Smit EF; Senan S; Hartemink KJ; Damhuis RA
    J Thorac Oncol; 2016 Apr; 11(4):566-72. PubMed ID: 26773741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer.
    Ye JC; Ding L; Atay SM; Nieva JJ; McFadden PM; Chang E; Kim AW
    Semin Thorac Cardiovasc Surg; 2020; 32(1):153-159. PubMed ID: 31220530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.
    Behera M; Steuer CE; Liu Y; Fernandez F; Fu C; Higgins KA; Gillespie TW; Pakkala S; Pillai RN; Force S; Belani CP; Khuri FR; Curran WJ; Ramalingam SS
    Oncologist; 2020 Jun; 25(6):e964-e975. PubMed ID: 31943520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response.
    Ziel E; Hermann G; Sen N; Bonomi P; Liptay MJ; Fidler MJ; Batus M; Warren WH; Chmielewski G; Sher DJ
    J Thorac Oncol; 2015 Oct; 10(10):1475-80. PubMed ID: 26398822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Montemuiño S; Dios NR; Martín M; Taboada B; Calvo-Crespo P; Samper-Ots MP; López-Guerra JL; López-Mata M; Jové-Teixidó J; Díaz-Díaz V; Ingunza-Barón L; Murcia-Mejía M; Chust M; García-Cañibano T; Couselo ML; Puertas MM; Cerro ED; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Couñago F
    Rep Pract Oncol Radiother; 2020; 25(3):447-455. PubMed ID: 32477011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment.
    Guberina N; Pöttgen C; Schuler M; Guberina M; Stamatis G; Plönes T; Metzenmacher M; Theegarten D; Gauler T; Darwiche K; Aigner C; Eberhardt WEE; Stuschke M
    Radiat Oncol; 2022 Jul; 17(1):126. PubMed ID: 35842712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.